🇺🇸 FDA
Patent

US 11497781

Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor

granted A61KA61K35/761A61K39/3955

Quick answer

US patent 11497781 (Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor) held by CG ONCOLOGY, INC. expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CG ONCOLOGY, INC.
Grant date
Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K35/761, A61K39/3955, A61P, A61P35/02